Cannabinoid hyperemesis syndrome: prevalence and management in an era of cannabis legalization.
| Autor: | Stubbs JJ; Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA., McCallum R; Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of investigative medicine : the official publication of the American Federation for Clinical Research [J Investig Med] 2024 Feb; Vol. 72 (2), pp. 171-177. Date of Electronic Publication: 2024 Jan 10. |
| DOI: | 10.1177/10815589231217495 |
| Abstrakt: | As more states legalize cannabinoid products for recreational use and medicinal purposes, the prevalence of cannabinoid hyperemesis syndrome has become increasingly common. Yet, it remains unrecognized to many healthcare providers along with the most efficacious treatments. Cannabinoid hyperemesis syndrome most often presents with episodic vomiting secondary to chronic daily cannabis use over several months to years. Patients often complain of nausea and abdominal pain that is improved by taking hot showers or baths. Symptoms are alleviated with the cessation of cannabis use over a period of 6-12 months. Treatment for acute attacks often consists of parenteral benzodiazepines in the inpatient setting. Long-term management and prevention of further attacks are aided by tricyclic antidepressants such as amitriptyline with a dose range of 50-200 mg/d. Once a patient is in remission, amitriptyline can be tapered slowly. As cannabis becomes more widely available and accepted in the continental United States, so must education on the diagnosis of cannabinoid hyperemesis syndrome and treatment strategies. Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|